As high as 94% of cancer patients developed a good immune response to COVID-19 vaccine three to four weeks after getting their second dose, according to a new study.
A team of researchers surveyed 131 cancer patients to study immune response to mRNA COVID vaccines. Of them, 124 developed antibodies to coronavirus, but seven did not.
Though the second group is much smaller, it has raised questions on how concerns about their protection against the potentially deadly virus can be addressed.
“We could not find any antibodies against the virus in those patients,” said Dimpy P Shah of the Mays Cancer Center. “That has implications for the future. Should we provide a third dose of vaccine after cancer therapy has completed in certain high-risk patients?”
The study, however, didn’t examine the highly transmissible Delta variant and other mutants. The response of infection-fighting T cells and B cells in patients with cancer was also not analyzed.
Cancer patients who are infected by coronavirus are among those who have a much higher risk of severe complications and mortality. Not much data is available on vaccine efficacy in such high-risk patients.
Bhubaneswar: After Odisha’s Forest Minister Ganesh Ram Singh Khuntia’s direction for through probe into elephant…
Bhubaneswar: Following backlash on social media, popular e-commerce platform Meesho on Tuesday removed t-shirts, featuring…
New Delhi: India has taken the first step in its attempt to host the 2036…
Bhadrak: The Railways on Tuesday launched a probe into allegations of bullets being fired at…
Bhubaneswar: Odisha Vigilance on Tuesday arrested senior assistant in Additional District Public Health Office (Family…
Bhubaneswar: The regional centre of India Meteorological Department (IMD) has sounded yellow warning for four…
Bhubaneswar: Odisha’s Deputy Chief Minister Pravati Parida held a meeting with the Indian High Commissioner…
Bhubaneswar: Chief Minister Mohan Charan Majhi on Tuesday informed about the central government's plans for…